Lupin drops on reports of USFDA inspection at Goa facility
Lupin slips over 7% to Rs1736.5, on reports that USFDA cited nine observations in its inspection of the company's Goa facility last week
Lupin fell over 7%, touching to Rs1736.5, on reports that the USFDA n cited nine observations in its inspection of the company's Goa facility last week.
Wipro aspire to deliver 12-14% revenue growth in FY17
Wipro Ltd’s chief executive officer (CEO) Abidali Neemuchwala has set an ambitious revenue growth target of 12-14% for fiscal 2017, Wipro, which will grow at around 4% for FY16, will have 5% incremental growth in the next fiscal, attributing to the $371 million in revenue it got from the four buyouts it made over the last 12 months.
Aurobindo gets USFDA nod for Ibandronate Sodium tablets
Pharma major Aurobindo Pharma said that it has received USFDA approval for Ibandronate Sodium Tablets.
The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Boniva® Tablets of Hoffman-La Roche Inc, the company said in a filing to the Bombay Stock Exchange.
Ibandronate Sodium Tablets is used in the treatment and prevention of osteoporosis in postmenopausal women.
Zee Ent board approves acquisition of stake
Zee Entertainment Enterprises has announced that the Board of Directors of the Company at its meeting held on March 14, 2016, has approved in-principle an acquisition of 100% equity stake in Fly By Wire International Private Ltd.
Crompton Greaves goes ex-Consumer biz today
Crompton Greaves has gone ex-Consumer biz today (15th March 2016). We have valued Consumer business at Rs105 and power and industrial business at Rs65 per share.
The Board of Directors of the company has fixed March 16, 2016 as the ‘Record Date’ for the purpose of reckoning names of the equity shareholders of the company entitled to receive shares of Crompton Greaves Consumer Electrical business.
Read our more services below:
CapitalStars Financial Research Financial Advisory Services
www.capitalstars.com | T:+91-731-6790000,6669900
No comments:
Post a Comment